• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

表皮生长因子刺激的卵巢癌细胞迁移与尿激酶型纤溶酶原激活物受体的内化减少、表面表达增加和脱落增加有关。

EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.

作者信息

Henic Emir, Sixt Michael, Hansson Stefan, Høyer-Hansen Gunilla, Casslén Bertil

机构信息

Department of Obstetrics & Gynecology, University Hospital, SE-221 85 Lund, Sweden.

出版信息

Gynecol Oncol. 2006 Apr;101(1):28-39. doi: 10.1016/j.ygyno.2005.09.038. Epub 2005 Nov 2.

DOI:10.1016/j.ygyno.2005.09.038
PMID:16263158
Abstract

OBJECTIVES

The EGFR is expressed in malignant ovarian tumor tissue, and tissue content of EGFR has been directly associated with poor prognosis in patients with ovarian cancer. The uPA system plays a role in pericellular proteolysis, cell migration, invasion, and is over-expressed in ovarian cancer. This study explored the effects of EGF on uPAR expression in the ovarian cancer cell line OVCAR-3.

METHODS

We used OVCAR-3 cells and the following methods: cell migration assay, time-lapse video microscopy, real-time PCR, assays for cellular binding of 125I-uPA and cellular degradation of 125I-uPA:PAI-1 complex, biosynthetic labeling using 35S-methionin, Western blot, Northern blot, and ELISAs for uPA, PAI-1, and uPAR.

RESULTS

EGF up-regulates both protein and mRNA not only for uPAR, but also for the ligand uPA and its inhibitor PAI-1. Cell surface uPAR, in control as well as EGF-stimulated cells, is present only in the intact, not the cleaved, form. Ligand binding experiments showed an increase of endogenously occupied uPAR, whereas non-occupied receptor sites were not increased. In addition, EGF treatment resulted in decreased degradation of radiolabeled uPA:PAI-1 complex. This suggests decreased internalization of uPAR, since the complex is internalized together with uPAR. Like EGF, colchicine, which inhibits endocytosis, increased cell surface expression of uPAR. In addition, we found an immediate increase of uPAR after exposing the cells to EGF and this was accompanied by a transient increase of cell migration. The increase of cell surface uPAR in response to EGF is accompanied by increased release of the soluble form of uPAR (suPAR) to the medium as well as by increased cell migration. Both uPAR and suPAR increased in cells treated with the endocytosis inhibitor colchicine even though cell migration was inhibited, suggesting that the mechanism of uPAR shedding is not related to cell migration.

CONCLUSION

Increased cell surface uPAR in response to EGF stimulation results from mobilization of uPAR from detergent-resistant domains, increased expression of uPAR mRNA, and decreased internalization and degradation of uPAR. Both the anti-uPAR antibody R3, which inhibits binding of uPA, and the EGFR phosphorylation inhibitor Iressa inhibited cell migration in response to uPA as well as to EGF, suggesting that EGFR and uPAR are engaged in the same multiprotein assembly on the cell surface.

摘要

目的

表皮生长因子受体(EGFR)在恶性卵巢肿瘤组织中表达,且EGFR的组织含量与卵巢癌患者的不良预后直接相关。尿激酶型纤溶酶原激活物(uPA)系统在细胞周围蛋白水解、细胞迁移和侵袭中起作用,且在卵巢癌中过表达。本研究探讨了表皮生长因子(EGF)对卵巢癌细胞系OVCAR-3中uPAR表达的影响。

方法

我们使用OVCAR-3细胞并采用以下方法:细胞迁移试验、延时视频显微镜观察、实时聚合酶链反应(PCR)、125I-uPA细胞结合试验及125I-uPA:PAI-1复合物细胞降解试验、用35S-蛋氨酸进行生物合成标记、蛋白质印迹法、RNA印迹法以及uPA、PAI-1和uPAR的酶联免疫吸附测定(ELISA)。

结果

EGF不仅上调uPAR的蛋白和信使核糖核酸(mRNA)水平,还上调配体uPA及其抑制剂PAI-1的蛋白和mRNA水平。在对照细胞以及EGF刺激的细胞中,细胞表面的uPAR仅以完整形式存在,而非裂解形式。配体结合实验表明内源性占据的uPAR增加,而未占据的受体位点未增加。此外,EGF处理导致放射性标记的uPA:PAI-1复合物降解减少。这表明uPAR的内化减少,因为该复合物与uPAR一起被内化。与EGF一样,抑制内吞作用的秋水仙碱增加了uPAR的细胞表面表达。此外,我们发现细胞暴露于EGF后uPAR立即增加,同时细胞迁移短暂增加。EGF刺激引起的细胞表面uPAR增加伴随着uPAR可溶性形式(suPAR)向培养基中的释放增加以及细胞迁移增加。在用内吞作用抑制剂秋水仙碱处理的细胞中,尽管细胞迁移受到抑制,但uPAR和suPAR均增加,这表明uPAR脱落的机制与细胞迁移无关。

结论

EGF刺激导致细胞表面uPAR增加是由于uPAR从抗去污剂结构域动员、uPAR mRNA表达增加以及uPAR内化和降解减少所致。抑制uPA结合的抗uPAR抗体R3和EGFR磷酸化抑制剂易瑞沙均抑制了细胞对uPA以及EGF的迁移反应,这表明EGFR和uPAR参与了细胞表面相同的多蛋白组装。

相似文献

1
EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.表皮生长因子刺激的卵巢癌细胞迁移与尿激酶型纤溶酶原激活物受体的内化减少、表面表达增加和脱落增加有关。
Gynecol Oncol. 2006 Apr;101(1):28-39. doi: 10.1016/j.ygyno.2005.09.038. Epub 2005 Nov 2.
2
Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.靶向人胰腺癌细胞中的尿激酶型纤溶酶原激活物受体可抑制c-Met和胰岛素样生长因子-I受体介导的迁移、侵袭以及小鼠原位肿瘤生长。
Cancer Res. 2005 Sep 1;65(17):7775-81. doi: 10.1158/0008-5472.CAN-05-0946.
3
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.尿激酶型纤溶酶原激活剂及其受体和1型抑制剂在子宫内膜癌中的临床相关性
Gynecol Oncol. 2001 Jan;80(1):48-55. doi: 10.1006/gyno.2000.6015.
4
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.乳腺肿瘤组织基质中的尿激酶系统与乳腺癌细胞侵袭
Int J Oncol. 2009 Jan;34(1):15-23.
5
Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.尿激酶型纤溶酶原激活物受体的抑制通过ERK/p38信号通路的调节抑制胰腺腺癌细胞的增殖和迁移。
Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1731-8. doi: 10.1016/j.biocel.2009.03.004. Epub 2009 Mar 21.
6
Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line.尿激酶受体的过表达增加了人骨肉瘤细胞系的基质侵袭能力,而不改变细胞迁移能力。
Cancer Res. 1993 Jul 1;53(13):3109-17.
7
Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle.月经周期中子宫内膜组织中尿激酶型纤溶酶原激活剂(uPA)、其受体(uPAR)及其抑制剂(PAI-1)mRNA和蛋白的差异定位与表达。
Mol Hum Reprod. 2004 Sep;10(9):655-63. doi: 10.1093/molehr/gah081. Epub 2004 Jul 8.
8
Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.降钙素抑制乳腺癌细胞的侵袭:尿激酶型纤溶酶原激活剂(uPA)及uPA受体的作用
Int J Oncol. 2006 Apr;28(4):807-14.
9
Posttranscriptional regulation of urokinase receptor expression by heterogeneous nuclear ribonuclear protein C.异质性细胞核核糖核蛋白C对尿激酶受体表达的转录后调控
Biochemistry. 2008 Jun 17;47(24):6508-17. doi: 10.1021/bi702338y. Epub 2008 May 22.
10
Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro.尿激酶型纤溶酶原激活物受体参与胰岛素样生长因子诱导的横纹肌肉瘤细胞体外迁移。
J Cell Physiol. 2003 Oct;197(1):131-8. doi: 10.1002/jcp.10352.

引用本文的文献

1
Circulating levels of soluble urokinase plasminogen activator receptor predict outcome after resection of biliary tract cancer.可溶性尿激酶型纤溶酶原激活物受体的循环水平可预测胆管癌切除术后的预后。
JHEP Rep. 2020 Jan 31;2(2):100080. doi: 10.1016/j.jhepr.2020.100080. eCollection 2020 Apr.
2
Peroxiporins in Cancer.过氧化物酶体在癌症中的作用。
Int J Mol Sci. 2019 Mar 19;20(6):1371. doi: 10.3390/ijms20061371.
3
Vitronectin in the ascites of human ovarian carcinoma acts as a potent chemoattractant for ovarian carcinoma: Implication for metastasis by cancer stem cells.
人卵巢癌腹水中的玻连蛋白可作为卵巢癌的强效趋化因子:对癌症干细胞转移的影响。
J Cancer Stem Cell Res. 2016;4. doi: 10.14343/JCSCR.2016.4e1005. Epub 2016 Nov 30.
4
Tumour microenvironments induce expression of urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes.肿瘤微环境诱导尿激酶型纤溶酶原激活物受体(uPAR)的表达并伴随明胶酶的激活。
PLoS One. 2014 Aug 26;9(8):e105929. doi: 10.1371/journal.pone.0105929. eCollection 2014.
5
EGFR/HER-targeted therapeutics in ovarian cancer.表皮生长因子受体/人表皮生长因子受体靶向治疗在卵巢癌中的应用。
Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11.
6
A cleavage-resistant urokinase plasminogen activator receptor exhibits dysregulated cell-surface clearance.一种不易断裂的尿激酶型纤溶酶原激活物受体表现出细胞表面清除的失调。
J Biol Chem. 2010 Apr 23;285(17):12595-603. doi: 10.1074/jbc.M109.008581. Epub 2010 Feb 22.
7
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.靶向上皮性卵巢癌的表皮生长因子受体:当前的认识与未来的挑战。
J Oncol. 2010;2010:568938. doi: 10.1155/2010/568938. Epub 2009 Nov 19.
8
Adhesion and migration of ovarian cancer cells on crosslinked laminin fibers nanofabricated by multiphoton excited photochemistry.多光子激发光化学交联层粘连蛋白纤维纳米结构上卵巢癌细胞的黏附和迁移。
Integr Biol (Camb). 2009 Jul;1(7):469-76. doi: 10.1039/b906310b. Epub 2009 Jun 11.
9
Activated epidermal growth factor receptor in ovarian cancer.卵巢癌中活化的表皮生长因子受体
Cancer Treat Res. 2009;149:203-26. doi: 10.1007/978-0-387-98094-2_10.